Ibandronate (drug) in Patients of Liver Cirrhosis With Hepatic Osteodystrophy
- Conditions
- Health Condition 1: K769- Liver disease, unspecified
- Registration Number
- CTRI/2023/09/057712
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1.Liver cirrhosis patients between 18 to 70 yrs with low risk esophageal varices and HOD (osteoporosis/osteopenia will be enrolled).
2.Patient and attendants willing to give informed consent
1.Age <18 years and > 70 years
2.Patients with prior history of fracture
3.History of upper GI bleed in last 2 months
4.Patients with post EVL ulcers
5.High risk esophageal varices or gastric varices without endoscopic treatment.
6.Active peptic ulcer
7.Severe vascular ectasia
8.Esophageal stricture
9.Achalasia
10.Creatinine clearance below 30ml/min
11.Malignancy(except HCC)
12.Hyperparathyroidism
13.Patients using NSAIDs, corticosteroids ,anticoagulants or ongoing alcohol beverages
14.Bisphosphonate hypersensitivity/Oral bisphosphonate within 12 months
15.Grade 2/3 ascites
16.Hepatic encephalopathy(Grade 3 &4)
17.Critically ill patients
18.Post LT patients
19.HRT within 6 mths
20.Pregnant and lactating women
21.Patient with bleeding disorders
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method